NEW YORK / Dec 04, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced that its Cardiac RMS subsidiary has signed a new contract with one of the largest hospital systems in Mississippi.
Under the agreement, in early 2025 Cardiac RMS by DocGo is scheduled to begin providing remote monitoring for nearly 3,000 patients with cardiac implantable electronic devices (“CIEDs”). This new contract marks Cardiac RMS’s launch into Mississippi and expands their pediatric customer base – reflecting the company’s ability to provide remote monitoring solutions across all age groups in this new geography.
Mississippi faces high rates of cardiovascular disease, limited access to specialized care in rural areas, and significant healthcare provider shortages that create unique challenges for delivering effective, timely care. Cardiac RMS’s remote monitoring will help reduce the need for frequent in-office visits and enable early interventions that can prevent serious complications, while also enhancing clinical efficiency by helping streamline operations, reduce hospital readmissions, and improve patient outcomes.
“Health systems are increasingly seeking solutions that empower patient-centered care and more effective resource management,” said Lee Bienstock, CEO of DocGo. “By partnering with Cardiac RMS, providers can ensure continuous oversight of cardiac device patients of all ages, helping to prevent complications, reduce hospitalizations, and enhance operational efficiency. This collaboration exemplifies how remote patient monitoring can be a vital component of a modern, proactive, value-based care strategy.”
Cardiac RMS by DocGo will provide continuous remote oversight of patients with CIEDs, including pacemakers, implantable cardioverter-defibrillators, implantable heart failure devices, and implantable loop recorders, which require regular monitoring to ensure proper function and to promptly detect any issues.
Through advanced technology and adaptable services, Cardiac RMS by DocGo continues to elevate the delivery of cardiac care services, helping providers improve outcomes and create seamless patient experiences.
About Cardiac RMS by DocGo
Cardiac RMS LLC is a clinical service partner specializing in remote monitoring of cardiac implantable electronic devices (CIEDs), including pacemakers, defibrillators, implantable loop recorders, and heart failure devices. Services also include Virtual Care Management and Remote Physiologic Monitoring (RPM) to support the treatment of chronic conditions. By enhancing care accessibility and streamlining remote care, Cardiac RMS by DocGo empowers providers to deliver proactive, patient-focused solutions that improve outcomes and reduce costs.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the Company’s plans, strategies, outcomes, and prospects, both business and financial, of the Company, including the provision of services by Cardiac RMS in Mississippi. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions. Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the Company’s ability to successfully implement its business strategy, including with respect to the provision of services in Mississippi; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts, including Cardiac RMS's new contract to provide services in Mississippi; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.
Last Trade: | US$4.22 |
Daily Change: | -0.07 -1.63 |
Daily Volume: | 192,709 |
Market Cap: | US$428.460M |
December 18, 2024 December 10, 2024 November 26, 2024 November 07, 2024 October 09, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB